SARS-CoV2 and immunosuppression: A double-edged sword

被引:34
|
作者
Lai, Quirino [1 ]
Spoletini, Gabriele [2 ]
Bianco, Giuseppe [2 ]
Graceffa, Dario [3 ]
Agnes, Salvatore [2 ]
Rossi, Massimo [2 ]
Lerut, Jan [4 ]
机构
[1] Sapienza Univ Rome, Hepatobiliary & Organ Transplantat Unit, Umberto Polyclin Rome 1, Viale Policlin 155, Rome, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Gen Surg & Liver Transplantat, Rome, Italy
[3] IRCCS, San Gallicano Dermatol Inst, Dept Clin Dermatol, Ctr Study & Treatment Psoriasis, Rome, Italy
[4] Univ Catholique Louvain UCL, Inst Expt & Clin Res IREC, Brussels, Belgium
关键词
Coronavirus; COVID-19; cyclosporine; SARS; steroids; tacrolimus; RESPIRATORY-SYNDROME SARS; MERS-COV INFECTION; CORTICOSTEROID TREATMENT; COVID-19; REPLICATION; THERAPY;
D O I
10.1111/tid.13404
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Severe acute respiratory syndrome Coronavirus 2 (SARS-Cov2) outbreak has caused a pandemic rapidly impacting on the way of life of the entire world. This impact in the specific setting of transplantation and immunosuppression has been poorly explored to date. Discordant data exist on the impact of previous coronavirus outbreaks on immunosuppressed patients. Overall, only a very limited number of cases have been reported in literature, suggesting that transplanted patients not necessarily present an increased risk of severe SARS-Cov2-related disease compared to the general population. We conducted a literature review related to the impact of immunosuppression on coronavirus infections including case reports and series describing immunosuppression management in transplant recipients. The role of steroids, calcineurin inhibitors, and mycophenolic acid has been explored more in detail. A point-in-time snapshot of the yet released literature and some considerations in relation to the use of immunosuppression in SARS-Cov2 infected transplant recipients are provided here for the physicians dealing with immunocompromised patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Increasing SR Ca uptake: a double-edged sword
    Valverde, Carlos A.
    Mattiazzi, Alicia
    JOURNAL OF PHYSIOLOGY-LONDON, 2022, 600 (06): : 1533 - 1534
  • [22] Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers
    Yang, Ruixin
    Yu, Yingyan
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (06): : 1530 - 1537
  • [23] Appropriate Use of Proton Pump Inhibitors: A Double-Edged Sword
    Lewis, Paul O.
    Covert, Kelly L.
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (03) : 218 - 219
  • [24] Caspase-8, a Double-Edged Sword for EPC Functioning
    Xiao, Qingzhong
    Xu, Qingbo
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (04) : 444 - 446
  • [25] A double-edged sword of using opioids and COVID-19: a toxicological view
    Ataei, Mahshid
    Shirazi, Farshad M.
    Lamarine, Roland J.
    Nakhaee, Samaneh
    Mehrpour, Omid
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2020, 15 (01)
  • [26] Regulated necrosis in COVID-19: A double-edged sword
    Sun, Chen
    Han, Yunze
    Zhang, Ruoyu
    Liu, Simon
    Wang, Jing
    Zhang, Yuqing
    Chen, Xuemei
    Jiang, Chao
    Wang, Junmin
    Fan, Xiaochong
    Wang, Jian
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] SARS-CoV2: Diagnostic tests available to the clinician
    Hadweh, Paul
    Orfanidou, Timoklia
    Tsiamita, Maria
    Timologos, Grigorios
    Papadopoulos, Theofanis
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2020, 23 : 8 - 14
  • [28] Immunosuppression is a Double-Edged Sword in COVID-19 Treatment: a Case Report of Rhino-Orbito-Cerebral Mucormycosis
    Sedaghattalab, Moslem
    Bagheri, Tahmineh
    Doustimotlagh, Amir H.
    CLINICAL LABORATORY, 2022, 68 (07) : 1484 - 1487
  • [29] International Trade and Letters of Credit: A Double-Edged Sword in Times of Crises
    Matthieu Crozet
    Banu Demir
    Beata Javorcik
    IMF Economic Review, 2022, 70 : 185 - 211
  • [30] Annexin A1: A double-edged sword as novel cancer biomarker
    Fu, Zhuqiong
    Zhang, Shanshan
    Wang, Baiqi
    Huang, Weiguo
    Zheng, Lulu
    Cheng, Ailan
    CLINICA CHIMICA ACTA, 2020, 504 : 36 - 42